Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statin Comparative Studies Needed, Oregon Drug Effectiveness Review Project Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

DERP wants comparative-effectiveness study on LDL-c lowering capabilities and adverse events.

You may also be interested in...



Medco Savings Tool Spotlights Consumer Reports’ “Best Buy” Drugs

PBM will feature link to Consumer Reports Best Buy Drugs for certain medication classes.

AstraZeneca’s Crestor Targets High Risk Patients, Delivers High Sales

Crestor sales grew 47% in the second quarter; entry of generic simvastatin caused some expected “disruption” in the marketplace.

Lipitor Is Pound-Wise Versus Generic Zocor, Pfizer IDEAL Cost Study Says

When total healthcare costs are considered, atorvastatin is more cost-effective than simvastatin even when Zocor is discounted 50% from its current price, Pfizer analysis says.

Topics

UsernamePublicRestriction

Register

PS064722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel